Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Net Margin (2020 - 2025)

Tango Therapeutics has reported Net Margin over the past 6 years, most recently at 29.52% for Q3 2025.

  • Quarterly results put Net Margin at 29.52% for Q3 2025, up 28081.0% from a year ago — trailing twelve months through Dec 2025 was 162.85% (up 14687.0% YoY), and the annual figure for FY2025 was 162.85%, up 14688.0%.
  • Net Margin for Q3 2025 was 29.52% at Tango Therapeutics, up from 1221.41% in the prior quarter.
  • Over the last five years, Net Margin for TNGX hit a ceiling of 29.52% in Q3 2025 and a floor of 1221.41% in Q2 2025.
  • Median Net Margin over the past 5 years was 419.8% (2022), compared with a mean of 411.76%.
  • Biggest five-year swings in Net Margin: soared 28862bps in 2023 and later crashed -109285bps in 2025.
  • Tango Therapeutics' Net Margin stood at 385.83% in 2021, then decreased by -17bps to 453.28% in 2022, then decreased by -25bps to 566.19% in 2023, then crashed by -62bps to 914.99% in 2024, then surged by 103bps to 29.52% in 2025.
  • The last three reported values for Net Margin were 29.52% (Q3 2025), 1221.41% (Q2 2025), and 739.54% (Q1 2025) per Business Quant data.